Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRLX101 and Enzalutamide in mCRPC
NCT03531827Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2019
- Primary completion
- May 2021
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of CRLX101 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by National Cancer Institute. Started Mar 2019; status: terminated.
02
Drugs
CRLX101
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03531827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03531827.